We are also advancing discovery programs in additional neuromuscular and neurological indications to continue to leverage the broad potential of PepGen’s Enhanced Delivery Oligonucleotide (EDO) technology.
Pipeline
Therapies with the
potential to halt disease
progression
PepGen is advancing a pipeline of disease-modifying, peptide-conjugated oligonucleotide candidates to treat neuromuscular and neurological disorders, beginning with Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). These treatments have the potential to halt the progression of these disorders.
PepGen’s clinical candidates for DMD and DM1 have demonstrated early signs of activity as well as being generally well tolerated, and we are focused on continuing to advance these therapies through clinical trials.
